61032-41-5

Basic information

• Product Name: Methyl 4-(benzyloxy)-5-methoxy-2-nitrobenzoate
• Synonyms: Methyl 4-(benzyloxy)-5-methoxy-2-nitrobenzoate;4-Benzyloxy-5-methoxy-2-nitrobenzoic acid methyl ester;Methyl 5-methoxy-2-nitro-4-(benzyloxy)benzoate;ethyl 4-(benzyloxy)-5-Methoxy-2-nitrobenzoate;Benzoic acid, 5-Methoxy-2-nitro-4-(phenylMethoxy)-, Methyl ester
• CAS NO: 61032-41-5
• Molecular Formula: C₁₆H₁₅NO₆
• Molecular Weight: 317
• Mol File: 61032-41-5.mol

Chemical Properties

• Boiling Point: 482.4±40.0 °C(Predicted)
• Appearance: /
• Density: 1.280
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Methyl 4-(benzyloxy)-5-methoxy-2-nitrobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-(benzyloxy)-5-methoxy-2-nitrobenzoate(61032-41-5)
• EPA Substance Registry System: Methyl 4-(benzyloxy)-5-methoxy-2-nitrobenzoate(61032-41-5)

Safety Data

• Hazardous Substances Data: 61032-41-5(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Methyl 4-(benzyloxy)-5-methoxy-2-nitrobenzoate is used as a building block for the synthesis of complex organic molecules. Its presence of different functional groups allows for various chemical reactions, making it a versatile compound in the field of organic synthesis.
Used in Medicinal Chemistry:
In the pharmaceutical industry, Methyl 4-(benzyloxy)-5-methoxy-2-nitrobenzoate is used as a key intermediate in the production of various pharmaceuticals. Its unique structure and functional groups enable the development of new drugs with potential therapeutic applications.
Used in Fine Chemicals Production:
Methyl 4-(benzyloxy)-5-methoxy-2-nitrobenzoate is also utilized in the production of fine chemicals, which are high-purity chemicals used in various applications such as research, analysis, and specialty manufacturing. Its versatility and reactivity make it a valuable component in the synthesis of these high-quality chemicals.

Upstream product

• 3943-74-6 4-hydroxy-3-methoxybenzoic acid methyl ester 
• 100-39-0 benzyl bromide 
• 91203-74-6 4-benzyloxy-3-methoxybenzoic acid benzyl ester 
• 67-56-1 methanol 
• 60547-92-4 4-(benzyloxy)-5-methoxy-2-nitrobenzoic acid 
• 56441-97-5 methyl 4-(benzyloxy)-3-methoxybenzoate 
• 108-24-7 acetic anhydride 
• 111627-40-8 methyl 4-(3-chloropropoxy)-3-methoxybenzoate 
• 2426-87-1 3-methoxy-4-(phenylmethoxy)benzaldehyde 
• 121-33-5 vanillin 
• 121-34-6 3-methoxy-4-hydroxybenzoic acid 
• 100-44-7 benzyl chloride 
• 27883-60-9 4-hydroxy-5-methoxy-2-nitrobenzoic acid methyl ester 
• 1486-53-9 4-(benzyloxy)-3-methoxybenzoic acid 

Downstream Products

• 61032-42-6 methyl 2-amino-4-(benzyloxy)-5-methoxybenzoate 
• 364793-69-1 methyl 2-amino-5-methoxy-4-{[(trifluoromethyl)-sulfonyl]oxy}benzoate 
• 364793-68-0 5-methoxy-2-nitro-4-trifluoromethanesulfonyloxy-benzoic acid methyl ester 
• 364793-72-6 (4-chloro-3-cyano-6-methoxy-7-quinolyl)trifluoromethanesulfonate 
• 364793-71-5 3-cyano-6-methoxy-4-oxo-1,4-dihydro-7-quinolinyl trifluoromethanesulfonate 
• 364793-73-7 3-cyano-4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxyquinolin-7-yl trifluoromethanesulfonate 
• 848092-84-2 methyl 2-amino-4-hydroxy-5-methoxybenzoate 
• 27883-60-9 4-hydroxy-5-methoxy-2-nitrobenzoic acid methyl ester 
• 1188908-02-2 1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-hydroxy-6-methoxyquinazolin-4-yloxy)phenyl)urea 
• 1188908-03-3 C₂₂H₁₉N₃O₃ 
• 1188908-04-4 4-(3-aminophenoxy)-6-methoxyquinazolin-7-ol 
• 179688-01-8 7-benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one 
• 162012-72-8 7-hydroxy-6-methoxy-3,4-dihydroquinazolin-4-one 
• 179688-02-9 7-acetoxy-6-methoxy-3,4-dihydroquinazolin-4-one 

Relevant articles and documents

VISUAL DETECTION OF PBD INDUCED DNA CROSSLINKS

The present invention relates to the field of oncology, laboratory tools and methods, and especially anti-tumor DNA crosslinking agents. Most patients with advanced solid tumors develop resistance to chemotherapy due to the ability of cancer cells to repair or tolerate sustained DNA damages. The inventors showed that the compounds according to the present invention allow the detection and visualization of alkylated DNA damages induced by PBDs without altering their DNA crosslinking ability. This enables the study of the effect and properties of PBDs. In particular, the present invention relates new derivates of PBD molecules and their synthesis. The present invention also relates to a method for visualizing DNA crosslinking; to a method for assessing the resistance of a tumor to a crosslinking agent and to a method for identifying a molecule or treatment for improving the efficiency of a crosslinking agent.

COMPOSITIONS AND METHODS RELATED TO MOLECULAR CONJUGATION

The invention relates to activated Michael acceptor (AMA) compounds that can undergo conjugation with biomolecules containing Michael donor moieties, thereby providing plasma-stable antibody-drug conjugates (ADCs). Pharmaceutical compositions of the ADCs are disclosed as well. Also provided herein are a number of applications (e.g., therapeutic applications) in which the compositions are useful.

Structure–activity relationship study of novel quinazoline-based 1,6-naphthyridinones as MET inhibitors with potent antitumor efficacy

As a privileged scaffold, the quinazoline ring is widely used in the development of EGFR inhibitors, while few quinazoline-based MET inhibitors are reported. In our ongoing efforts to develop new MET-targeted anticancer drug candidates, a series of quinaz

FUSED HETEROCYCLIC BENZODIAZEPINE DERIVATIVES AND USES THEREOF

The present disclosure provides compounds and compositions capable of extending lifespan, and methods of use thereof.

NOVEL BENZODIAZEPINE DERIVATIVES AND USES THEREOF

The present disclosure provides compounds and compositions capable of extending lifespan, and methods of use thereof.

ISOQUINOLIDINOBENZODIAZEPINES

This disclosure provides novel isoquinolidinobenzodiazepines. These compounds can also be incorporated into antibody-drug conjugates.

ISOQUINOLIDINOBENZODIAZEPINE (IQB)-1(CHLOROMETHYL)-2,3-DIHYDRO-1H-BENZO[E]INDOLE (CBI) DIMERS

Provided herein are isoquinolidinobenzodiazepine (IQB)-1(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimers, antibody-drug conjugates comprising them and methods of use for killing cells and treating disease.

METHODS OF PREPARING INDOLINOBENZODIAZEPINE DERIVATIVES

The invention provides novel methods for preparing indolinobenzodiazepine monomer compounds and their synthetic precursors.

Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2

EGFR and VEGFR-2 are involved in pathological disorders and the progression of different kinds of tumors, the combined blockade of EGFR and VEGFR signaling pathways appears to be an attractive approach to cancer therapy. In this work, a series of 4-anilinoquinazoline derivatives containing substituted diaryl urea or glycine methyl ester moiety were designed and identified as EGFR and VEGFR-2 dual inhibitors. Compounds 19i, 19j and 19l exhibited the most potent inhibitory activities against EGFR (IC50?=?1?nM, 78?nM and 51?nM, respectively) and VEGFR-2 (IC50?=?79?nM, 14?nM and 14?nM, respectively), they showed good antiproliferative activities as well. Molecular docking established the interaction of 19i with the DFG-out conformation of VEGFR-2, suggesting that they might be type II kinase inhibitors.

PYRROLOBENZODIAZEPINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE

The invention provides antibody-drug conjugates comprising an antibody conjugated to a pyrrolobenzodiazepine drug moiety via a disulfide linker, pyrrolobenzodiazepine linker-drug intermediates, and methods of using the antibody-drug conjugates.